Keliximab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | CD4 |
| Clinical data | |
| Routes of administration | intravenous |
| Identifiers | |
| CAS Number | 174722-30-6 |
| ATC code | none |
Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC (1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
- ↑ WHO Drug Information
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
